Emerging Therapies Expected to Accelerate the Paroxysmal Nocturnal Hemoglobinuria Market Growth by 2036

Forecast for Paroxysmal Nocturnal Hemoglobinuria Market Through 2036

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and serious blood disorder that historically had limited treatment options until the landscape began to change after 2007 with the advent of new therapies. Recent insights suggest that the market for PNH is set for substantial growth, reflecting the promise of emerging therapies and the increasing prevalence of diagnosed cases.

Transformation in Treatment Options

Previously deemed life-threatening, the management of PNH underwent a transformation with the introduction of therapies targeting hemolysis and thrombosis—two critical factors contributing to the disorder's associated mortality. Approval of the anti-C5 complement inhibitor eculizumab marked a significant milestone. This therapy effectively reduced hemolysis, lowered the need for transfusions, and diminished thrombosis risk. Other FDA-approved therapies like ULTOMIRIS and EMPAVELI have established a new standard of care by focusing on complement inhibition strategies.

However, the limitations surrounding terminal complement inhibition have spurred the development of new treatment approaches. Recent approvals of medicines targeting proximal complement inhibition, such as FABHALTA, VOYDEYA, and PIASKY, are expanding the horizons for PNH treatment.

Market Dynamics

According to DelveInsight, the PNH market was valued at approximately USD 1.5 billion in 2025 across seven major markets, which encompass the United States, Germany, France, Italy, Spain, the UK, and Japan. Analysts project a compound annual growth rate (CAGR) of 7.1% leading up to 2036. This anticipated growth is attributed to several factors, including the introduction of novel therapies, advancements in clinical management, and heightened awareness leading to more diagnoses of PNH.

Five Promising Therapies Reshaping the Market
DelveInsight has highlighted five emerging therapies projected to significantly influence the treatment landscape for PNH:

1. Regeneron Pharmaceuticals' Pozelimab + Cemdisiran
This investigational dual therapy involves a monoclonal antibody designed to inhibit complement component C5, effectively preventing the hemolytic activity in PNH. Pozelimab’s development employs Regeneron’s VelocImmune® technology tailored to expedite the generation of human antibodies. Expected trial results regarding its efficacy when combined with cemdisiran are anticipated soon, paving the way for new clinical insights.

2. Novo Nordisk's Zaltenibart (OMS906)
Serving as an innovative monoclonal antibody targeting MASP-3, Zaltenibart's indication for PNH has been recognized by the FDA. Data from early-phase studies indicate a favorable safety profile, reinforcing its promise as a viable treatment option for PNH.

3. NovelMed Therapeutics' Ruxoprubart (NM8074)
This selective inhibitor of complement convertases represents an innovative class of therapy that preserves the classical pathway while inhibiting the alternative pathway, thus promising higher safety and efficacy for PNH patients. Encouraging results from Phase II trials suggest its further potential across various indications.

4. Kira Pharmaceuticals' KP104
A bifunctional biologic targeting both the alternative and terminal complement pathways distinguishes KP104 within the treatment options. Its formulation promises broad therapeutic benefits, greatly enhancing its capacity to address PNH and other complement-driven diseases.

5. NovelMed Therapeutics' NM5072
With its designation as an orphan drug for PNH, NM5072 has shown potential in preclinical studies addressing various disease states linked to complement dysregulation. Anticipated Phase II trials could further explore its clinical efficacy.

Conclusion

The paroxysmal nocturnal hemoglobinuria landscape is evolving with the introduction of innovative therapies aimed at better management outcomes. As these therapies trial and become commercially available, they are expected to address critical unmet medical needs, thus contributing to a growing and dynamic market. The future of PNH treatment looks promising, with ongoing research and development poised to reshape the approach to care in this complex disorder.